Glenmark Pharmaceuticals Ltd. News and Updates

Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news on Glenmark Pharmaceuticals Ltd. from all sources in a single place.

Glenmark Pharmaceuticals Ltd.

26 May 2025

1457.10

3.60%

Glenmark Pharmaceuticals Results Earnings Call for Q4FY25 & Full Year

Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.

audio

Glenmark Pharmaceuticals Ltd.

26 May 2025

1457.10

3.60%

Glenmark Pharma Share Price Slumps After Q4 Results Miss Estimates

NDTV Profit

Glenmark Pharma reported a 6.3% increase in consolidated revenue, reaching Rs 3,256 crore compared to Rs 3,063 crore in the same quarter last year.

Glenmark Pharmaceuticals Ltd. is trading above its 100 day SMA of 1436.5

Glenmark Pharmaceuticals Ltd.

26 May 2025

1457.10

3.60%

EU and lower R&D spending drive 4Q earnings

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) posted a marginally lower-than-expected operating performance in 4QFY25 (2%/5% miss on revenue/EBITDA). Elevated interest outgo and lower other income led to a 16% miss on earnings.

Glenmark Pharmaceuticals Ltd. is trading below its 150 day SMA of 1485.3

Glenmark Pharmaceuticals Ltd.

23 May 2025

1457.10

3.60%

Glenmark Pharmaceuticals Q4 Results: Company Swings To Profit

NDTV Profit

The company declared a dividend of Rs 2.5 apiece with a face value of Rs 2 each for fiscal 2025.

Glenmark Pharmaceuticals Ltd. has gained 26.05% in the last 1 Year

Glenmark Pharmaceuticals Ltd.

06 May 2025

1457.10

3.60%

Glenmark Pharma shares up 2% after FDA grants fast track status to cancer drug

Economic Times

Glenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated RRMM patients. The tri-specific antibody showed high response rates and a favorable safety profile in early trials. Complete results will be presented at ASCO 2025. The stock rose 2.2% on Monday, with analysts maintaining a 'Buy' rating.

Glenmark Pharmaceuticals Ltd. has gained 26.05% in the last 1 Year

Glenmark Pharmaceuticals Ltd.

18 Apr 2025

1457.10

3.60%

CDSCO flags spurious batch of Telma, 131 other drugs fail quality tests

Business Standard

Telma 40 is manufactured by Glenmark Pharmaceuticals and is prescribed for controlling high blood pressure, particularly in individuals prone to water retention or heart failure

Glenmark Pharmaceuticals Ltd.'s price crossed above 30Day SMA today

Glenmark Pharmaceuticals Ltd.

30 Mar 2025, 09:11PM

1457.10

3.60%

Spurious batch of Telma H flagged, 103 other drugs fail CDSCO tests

Business Standard

Telma H is manufactured by Glenmark Pharmaceuticals and is prescribed for controlling high blood pressure, particularly in individuals prone to water retention or heart failure

Glenmark Pharmaceuticals Ltd.'s price crossed above 100Day SMA today

Glenmark Pharmaceuticals Ltd.

21 Mar 2025

1457.10

3.60%

Glenmark Pharma share rises 2% on securing USFDA nod; key details here

Business Standard

Glenmark Pharma's stock rose after it said Glenmark Pharmaceuticals Inc., USA, has received final approval from the USFDA for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%

Glenmark Pharmaceuticals Ltd.'s price crossed above 50Day SMA today

Glenmark Pharmaceuticals Ltd.

12 Mar 2025

1457.10

3.60%

Glenmark launches Empagliflozin for diabetes in India under Glempa brand

Business Standard

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'?Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range ..